open access

Vol 25, No 2 (2020)
Original research articles
Published online: 2020-03-01
Submitted: 2019-07-14
Get Citation

The impact of local control timing in Ewing sarcoma

Samer Salah, Hadeel Halalsheh, Fawzi Abuhijla, Taleb Ismael, Sameer Yaser, Ahmad Shehadeh, Samer Abdelal, Iyad Sultan, Abdelatif Almousa, Ramiz Abu Hijlih
DOI: 10.1016/j.rpor.2020.02.001
·
Rep Pract Oncol Radiother 2020;25(2):255-259.

open access

Vol 25, No 2 (2020)
Original research articles
Published online: 2020-03-01
Submitted: 2019-07-14

Abstract

Aim

To assess the impact of delay in local control on survival outcomes of Ewing sarcoma (ES) patients.

Background

The cornerstone of therapy of localized ES includes chemotherapy and local control with surgery or radiotherapy. We sought to assess the impact of delay (>15 weeks) in timing of local control on survival outcomes of ES patients.

Methods

Data of consecutive patients with primary non-metastatic ES of the extremities, treated at a single institution were collected. The impact of delay of timing for local control, demographics, and disease characteristics on overall survival (OS) was analyzed.

Results

A total of 43 patients with ES of the extremity were included. All patients received neoadjuvant chemotherapy. Local control was by surgery in 36 patients and definitive radiation in 7. A total of 16 patients had delay in local control. At a median follow of up of 48 months, patients with delay in local control had significantly inferior OS compared to those with optimal local control timing (5-year OS 56% vs. 80%, respectively, p = 0.044). Other factors that predicted inferior OS included definitive radiation as opposed to definitive surgery (5-year OS 25% vs. 79%, respectively, p = 0.041) and tumor necrosis <90% as opposed to ≥90% (5-year OS 55% vs. 90%, respectively, p = 0.01).

Conclusion

Delay in definitive therapy, local control with radiation as opposed to surgery and poor post-chemotherapy tumor necrosis predict inferior OS in ES. Adopting strategies to minimize delay in local control could improve survival outcomes.

Abstract

Aim

To assess the impact of delay in local control on survival outcomes of Ewing sarcoma (ES) patients.

Background

The cornerstone of therapy of localized ES includes chemotherapy and local control with surgery or radiotherapy. We sought to assess the impact of delay (>15 weeks) in timing of local control on survival outcomes of ES patients.

Methods

Data of consecutive patients with primary non-metastatic ES of the extremities, treated at a single institution were collected. The impact of delay of timing for local control, demographics, and disease characteristics on overall survival (OS) was analyzed.

Results

A total of 43 patients with ES of the extremity were included. All patients received neoadjuvant chemotherapy. Local control was by surgery in 36 patients and definitive radiation in 7. A total of 16 patients had delay in local control. At a median follow of up of 48 months, patients with delay in local control had significantly inferior OS compared to those with optimal local control timing (5-year OS 56% vs. 80%, respectively, p = 0.044). Other factors that predicted inferior OS included definitive radiation as opposed to definitive surgery (5-year OS 25% vs. 79%, respectively, p = 0.041) and tumor necrosis <90% as opposed to ≥90% (5-year OS 55% vs. 90%, respectively, p = 0.01).

Conclusion

Delay in definitive therapy, local control with radiation as opposed to surgery and poor post-chemotherapy tumor necrosis predict inferior OS in ES. Adopting strategies to minimize delay in local control could improve survival outcomes.

Get Citation

Keywords

Ewing sarcoma; Local control; Radiotherapy; Outcomes

About this article
Title

The impact of local control timing in Ewing sarcoma

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 25, No 2 (2020)

Pages

255-259

Published online

2020-03-01

DOI

10.1016/j.rpor.2020.02.001

Bibliographic record

Rep Pract Oncol Radiother 2020;25(2):255-259.

Keywords

Ewing sarcoma
Local control
Radiotherapy
Outcomes

Authors

Samer Salah
Hadeel Halalsheh
Fawzi Abuhijla
Taleb Ismael
Sameer Yaser
Ahmad Shehadeh
Samer Abdelal
Iyad Sultan
Abdelatif Almousa
Ramiz Abu Hijlih

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl